{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122824","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.567878+00:00","generated_at":"2026-05-30T03:42:38.259752+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MBX Biosciences Q3 net loss $18.1M; cash $277M funds into mid-2027; IPO raised $251M","bullets":["Net loss for Q3 2024 was $18.1M vs $10.2M in Q3 2023; R&D spend rose to $16.7M from $9.1M.","Cash, equivalents and marketable securities $277.1M as of Sep 30, 2024 (up from $80.7M at Dec 31, 2023).","IPO and Series C gross proceeds totaled approximately $251.2M.","Phase 1 trial of MBX 1416 (post-bariatric hypoglycemia) last subject visit by late Nov 2024; topline results early Jan 2025.","Phase 2 Avail trial of MBX 2109 (hypoparathyroidism) enrollment completion expected Q1 2025; topline results Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122824","json":"https://secwatch.observer/filing/0000950170-24-122824.json","markdown":"https://secwatch.observer/filing/0000950170-24-122824.md","text":"https://secwatch.observer/filing/0000950170-24-122824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024122824/0000950170-24-122824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024122824/mbx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:42:38.259752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}